Shares of Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $7.50.
LUNG has been the subject of several analyst reports. Canaccord Genuity Group set a $5.00 target price on shares of Pulmonx in a research report on Wednesday, October 28th. Weiss Ratings lowered shares of Pulmonx from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday. Stifel Nicolaus upped their price target on Pulmonx from $2.50 to $4.00 and gave the company a "buy" rating in a research report on Wednesday, October 28th. Loop Capital set a $7.00 target price on shares of Pulmonx in a report on Wednesday. Finally, Lucid Cap Mkts initiated coverage on Pulmonx in a research report on Wednesday. They set a "strong-buy" rating on the stock.
Check Out Our Latest Stock Report on Pulmonx
Pulmonx Stock Up 1.9%
NASDAQ:LUNG opened at $2.74 on Friday. Pulmonx has a 12-month low of $1.13 and a 12-month high of $3.25. The company has a quick ratio of 3.31, a current ratio of 4.05 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $119.33 million, a P/E ratio of -2.71 and a beta of 0.19. The stock's fifty day simple moving average is $2.19 and its 200-day simple moving average is $1.73.
Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its earnings results on Tuesday, October 27th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. The firm had revenue of $22.84 million during the quarter, compared to analyst estimates of $21.93 million. Pulmonx had a negative net margin of 47.93% and a negative return on equity of 98.23%. Equities research analysts expect that Pulmonx will post -0.98 earnings per share for the current year.
Insider Activity
In related news, CEO Glendon French, III sold 41,882 shares of the business's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $94,653.32. Following the transaction, the chief executive officer owned 1,137,936 shares in the company, valued at $2,571,735.36. The trade was a 3.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Srikanth Radhakrishnan sold 14,245 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $32,193.70. Following the transaction, the insider directly owned 316,994 shares in the company, valued at approximately $716,406.44. This represents a 4.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 78,340 shares of company stock worth $177,048 in the last quarter. 7.50% of the stock is owned by corporate insiders.
Institutional Trading of Pulmonx
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LUNG. Sei Investments Co. bought a new position in Pulmonx in the first quarter worth approximately $31,000. Empowered Funds LLC bought a new stake in Pulmonx during the 3rd quarter valued at $66,000. Engineers Gate Manager LP increased its stake in Pulmonx by 11.5% during the 2nd quarter. Engineers Gate Manager LP now owns 62,589 shares of the company's stock valued at $81,000 after purchasing an additional 6,438 shares in the last quarter. Ieq Capital LLC acquired a new position in Pulmonx during the second quarter worth $90,000. Finally, Algert Global LLC lifted its stake in shares of Pulmonx by 15.2% in the second quarter. Algert Global LLC now owns 98,332 shares of the company's stock valued at $128,000 after buying an additional 12,970 shares in the last quarter. 91.04% of the stock is owned by institutional investors.
About Pulmonx
(
Get Free Report)
Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company's Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pulmonx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.
While Pulmonx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.